GenieBiome utilizes a proprietary database of Asian microbiomes to develop targeted treatments for health issues such as metabolic disorders, gut imbalances, and immune deficiencies. By regulating gut microbiota, the company aims to enhance immune function and address the physiological impacts of various diseases.
Funding
$11M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many individuals, particularly in Asia, experience health issues such as metabolic disorders, gut imbalances, weakened immunity, and skin sensitivities due to imbalances in their gut microbiota. Traditional treatments often overlook the critical role of the gut microbiome in regulating overall health and immune response.
Solution
GenieBiome (G-NiiB) leverages a proprietary database of Asian microbiomes to develop targeted oral microbiome formulations that address specific health concerns. By analyzing the unique characteristics of Asian gut microbiota, G-NiiB creates precision micro-ecological formulas designed to restore balance and enhance immune function. Their approach focuses on modulating the gut microbiome to improve metabolic processes, strengthen immunity, and alleviate symptoms associated with various conditions, including gut problems, skin sensitivities, and post-viral syndromes. G-NiiB's products are supported by clinical data from Hong Kong universities, demonstrating their efficacy in improving gut health and overall well-being.
Target Audience
The primary target audience includes individuals in Asia seeking to improve their gut health, enhance their immune function, and address specific health issues such as metabolic disorders, skin sensitivities, and post-viral symptoms through microbiome modulation.
Features
- Proprietary database of Asian microbiomes for targeted formulation development
- SIM01: Oral micro-ecological formula designed to enhance immunity, with clinical studies published in The Lancet Infectious Diseases demonstrating efficacy in alleviating post-viral symptoms
- SMT04: Micro-ecological formula for promoting gut health and addressing intestinal imbalances
- SIM03: Micro-ecological formula for children's immunity, designed to build a rainbow of immune support
- Microencapsulation technology to protect live bacteria and ensure targeted delivery to the gut
- Ongoing research into innovative formulations for liver health and adult eczema